Advancing High-Risk Oncology Interventions: Promising Developments from ASCO 2026

Johnson & Johnson is driving progress in high-risk oncology interventions through more than 20 clinical and real-world studies presented at the 2026 ASCO Annual Meeting. By focusing on earlier therapeutic intervention and precision regimens, the company aims to improve outcomes in prostate cancer, multiple myeloma, and head and neck cancer. Central to this effort is late-breaking Phase 3 PROTEUS data for ERLEADA® (apalutamide) plus androgen deprivation therapy in the perioperative setting for high-risk localized or locally advanced prostate cancer.

Plenary Spotlight on Perioperative Prostate Cancer Care

The final analysis of the Phase 3 PROTEUS study demonstrated the safety and efficacy of perioperative ERLEADA® combined with hormone therapy before and after prostate surgery. This high-risk oncology intervention addresses a major unmet need, where recurrence rates remain high despite surgery. Selected to open the ASCO plenary session, these results underscore the potential of earlier androgen receptor inhibition to reduce micrometastatic burden and improve long-term cancer control.

Bispecific Therapies Move Earlier in Multiple Myeloma

Results from the Phase 3 MajesTEC-9 study reinforce TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a potential new standard as early as second line in relapsed or refractory multiple myeloma. Subgroup analyses from PERSEUS and CEPHEUS further confirm the consistent benefit of DARZALEX FASPRO® across cytogenetic risk profiles. Additional data on outpatient dosing, CAR-T outcomes, and health economics support safer, more convenient administration and stronger value propositions for earlier-line use.

Subcutaneous Innovation Reshapes Head and Neck Cancer Treatment

Pivotal Phase 1b/2 OrigAMI-4 results position RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as a meaningful option for recurrent or metastatic head and neck cancer after prior immunotherapy and chemotherapy. The subcutaneous formulation offers practical advantages in administration time and clinic efficiency. A trial-in-progress update for the Phase 3 OrigAMI-5 study in the first-line setting signals continued expansion of this bispecific antibody into earlier lines of therapy.

Value Implications for Market Access and Reimbursement

The breadth of Johnson & Johnson’s ASCO 2026 program carries important implications. Phase 3 evidence in high-risk oncology interventions, particularly perioperative prostate cancer and second-line multiple myeloma, strengthens the case for improved survival, reduced downstream costs, and favorable reimbursement. Emphasis on subcutaneous delivery across multiple assets aligns with the growing demand for outpatient administration that enhances patient experience while lowering system costs.